首页 | 本学科首页   官方微博 | 高级检索  
检索        

长期口服依托泊甙胶囊治疗肺癌和恶性淋巴瘤
引用本文:刘天星,鲍云华,俞受程,张伟京.长期口服依托泊甙胶囊治疗肺癌和恶性淋巴瘤[J].中国新药与临床杂志,1995(5).
作者姓名:刘天星  鲍云华  俞受程  张伟京
作者单位:中国人民解放军307医院
摘    要:用依托泊甙(Eto)胶囊口服用药联合化疗方案治疗肺癌和恶性淋巴瘤17人,并以10例静脉滴注Eto作对照。结果:口服Eto胶囊组总有效率为88%,对照组为60%。肺癌口服Eto胶囊治疗组有效率(89%)明显高于对照组(43%),P<0.05。2组毒副作用相似。提示:口服Eto胶囊联合化疗对肺癌和恶性淋巴瘤的疗效不低于静脉用药组,值得进一步研究。

关 键 词:依托泊甙  肺肿瘤  淋巴瘤  联合药物疗法

Chronic daily adminisitration of oral etoposide capsule in lung cancer and malignant lymphoma
LIU Tian-Xing, BAO Yun-Hua, YU Shou-Cheng, ZHANG Wei-Jing.Chronic daily adminisitration of oral etoposide capsule in lung cancer and malignant lymphoma[J].Chinese Journal of New Drugs and Clinical Remedies,1995(5).
Authors:LIU Tian-Xing  BAO Yun-Hua  YU Shou-Cheng  ZHANG Wei-Jing
Abstract:Seventeen patients with lung cancer and malignant lymphoma were treated with combination chemotherapy including oral etoposide (Eto). The efficacy of oral Eto was compared with that of iv in 10 patients in same chemotherapy regimen. The overall response rates were 88%(oral) and 60%(iv), respectively. In lung cancer patients, the response rate(89%) is oral treatment was higher than that(43%) in iv, P< 0.05. Toxic effects induced by Eto were not different between the two regimens. Our results showed that the curative effect in oral treatment was close to that in iv. As the patient number is not large enough, the results are preliminary and necessary to study further.
Keywords:etoposide  lung neoplasms  lymphoma  combinantion drug therapy  
本文献已被 CNKI 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号